• レポートコード:TPM-NV194 • 出版社/出版日:Transparency Market Research / 2019年10月28日 • レポート形態:英文、PDF、145ページ • 納品方法:Eメール • 産業分類:製薬 |
Single User | ¥857,660 (USD5,795) | ▷ お問い合わせ |
Multi User | ¥1,301,660 (USD8,795) | ▷ お問い合わせ |
Global Site License | ¥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、アトピー性皮膚炎治療薬の世界市場について調べ、アトピー性皮膚炎治療薬の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別(コルチコステロイド、PDE4阻害剤、生物製剤、皮膚バリア皮膚軟化剤、CNI免疫抑制剤、その他)分析、流通チャンネル別(病院薬局、小売薬局、オンライン薬局)分析、関連企業情報などをまとめました。 ・アトピー性皮膚炎治療薬の市場概要 ・アトピー性皮膚炎治療薬の市場動向 ・アトピー性皮膚炎治療薬の世界市場規模・予測 ・アトピー性皮膚炎治療薬市場:薬物クラス別(コルチコステロイド、PDE4阻害剤、生物製剤、皮膚バリア皮膚軟化剤、CNI免疫抑制剤、その他) ・アトピー性皮膚炎治療薬市場:流通チャンネル別(病院薬局、小売薬局、オンライン薬局) ・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米) ・競争環境・関連企業分析 |
According to a study published by BioMed Central, U.K – an electronic-only medical journal, it was found that, on a global level, ~15 – 20% children and ~1 – 3% adults suffer from atopic dermatitis (AD). The growing prevalence of this disease has triggered the demand for efficacious drugs in the atopic dermatitis drugs market.
Biologic drugs are projected for exponential growth during the forecast period. In 2018, biologic drugs accounted for the highest market share of ~42%, and continue to dominate the market share with a projected value of ~77% in 2027. Thus, it is evident that, healthcare companies in the atopic dermatitis drugs market are increasing research & development activities to improve the efficacy of biologic drugs in order to provide instant relief for patients.
Since atopic dermatitis has a high risk of recurrence, healthcare companies in the atopic dermatitis drugs market are identifying drugs that improve the functioning of the immune system by helping to fight off bacteria and viruses. For instance, in August 2019, Sanofi – a French multinational pharmaceutical company, announced the approval of Dupixent® (dupilumab) – a biologic drug to treat moderate-to-severe atopic dermatitis, by the European Commission.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Atopic Dermatitis Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, 2017–2027
5. Market Outlook
5.1. Disease Epidemiology
5.2. Pipeline Analysis
5.3. Recent Development
6. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Market Value Forecast by Drug Class, 2017–2027
6.2.1. Corticosteroids
6.2.2. PDE4 Inhibitors
6.2.3. Biologics
6.2.4. Skin Barrier Emollients
6.2.5. CNI Immunosuppressants
6.2.6. Others
6.3. Market Attractiveness by Drug Class
7. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Introduction & Definition
7.2. Market Value Forecast by Distribution Channel, 2017–2027
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
7.3. Market Attractiveness by Distribution Channel
8. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness by Country/Region
9. North America Atopic Dermatitis Drugs Market Analysis and Forecast
9.1. Introduction
9.2. Market Value Forecast by Drug Class, 2017–2027
9.2.1. Corticosteroids
9.2.2. PDE4 Inhibitors
9.2.3. Biologics
9.2.4. Skin Barrier Emollients
9.2.5. CNI Immunosuppressants
9.2.6. Others
9.3. Market Value Forecast by Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Atopic Dermatitis Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast by Drug Class, 2017–2027
10.2.1. Corticosteroids
10.2.2. PDE4 Inhibitors
10.2.3. Biologics
10.2.4. Skin Barrier Emollients
10.2.5. CNI Immunosuppressants
10.2.6. Others
10.3. Market Value Forecast by Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Atopic Dermatitis Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast by Drug Class, 2017–2027
11.2.1. Corticosteroids
11.2.2. PDE4 Inhibitors
11.2.3. Biologics
11.2.4. Skin Barrier Emollients
11.2.5. CNI Immunosuppressants
11.2.6. Others
11.3. Market Value Forecast by Distribution Channel, 2017–2027
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Atopic Dermatitis Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast by Drug Class, 2017–2027
12.2.1. Corticosteroids
12.2.2. PDE4 Inhibitors
12.2.3. Biologics
12.2.4. Skin Barrier Emollients
12.2.5. CNI Immunosuppressants
12.2.6. Others
12.3. Market Value Forecast by Distribution Channel, 2017–2027
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Atopic Dermatitis Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast by Drug Class, 2017–2027
13.2.1. Corticosteroids
13.2.2. PDE4 Inhibitors
13.2.3. Biologics
13.2.4. Skin Barrier Emollients
13.2.5. CNI Immunosuppressants
13.2.6. Others
13.3. Market Value Forecast by Distribution Channel, 2017–2027
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast by Country/Sub-region, 2017–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competitive Landscape
14.1. Company Profiles
14.1.1. Mylan N.V.
14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.1.2. Product Portfolio
14.1.1.3. SWOT Analysis
14.1.1.4. Strategic Overview
14.1.1.5. Financial Overview
14.1.2. Pfizer, Inc.
14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.2.2. Product Portfolio
14.1.2.3. SWOT Analysis
14.1.2.4. Strategic Overview
14.1.2.5. Financial Overview
14.1.3. LEO Pharma A/S
14.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.3.2. Product Portfolio
14.1.3.3. SWOT Analysis
14.1.3.4. Strategic Overview
14.1.3.5. Financial Overview
14.1.4. Teva Pharmaceutical Industries Ltd
14.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.4.2. Product Portfolio
14.1.4.3. SWOT Analysis
14.1.4.4. Strategic Overview
14.1.4.5. Financial Overview
14.1.5. Sanofi
14.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.5.2. Product Portfolio
14.1.5.3. SWOT Analysis
14.1.5.4. Strategic Overview
14.1.5.5. Financial Overview
14.1.6. Novartis AG
14.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.6.2. Product Portfolio
14.1.6.3. SWOT Analysis
14.1.6.4. Strategic Overview
14.1.6.5. Financial Overview